The SME initial public offering (IPO) of New Delhi-headquartered healthcare logistics, cold-chain phlebotomy, and diagnostic supply chain major Credent Connect N Care Limited (operating under its well-known commercial brand C3 Logistics) experienced a massive acceleration in demand on its second day of public bidding today, Friday, August 14, 2026.
Carrying an aggregate issue size of ₹93.90 crore set within a fixed price band parameter of ₹179 to ₹189 per share, the public offer marks one of the largest and most actively bid healthcare technology and logistics launches on the NSE Emerge platform this year.
By the close of its second session across the national bourses at 5:00 PM IST, central exchange matching engines logged valid electronic application tokens for 4,01,47,800 equity shares against a net public offer pool of 33,12,000 equity shares (excluding anchor allocations and the market maker quota). This brings the overall subscription baseline to 12.12 times.
Everyday retail individual investors and high-net-worth wealth accounts spearheaded the Day 2 volume surge, taking their quotas to 16.39x and 9.73x respectively, while institutional buyers expanded their participation to 6.45x ahead of Monday's final closing bell.
The multi-day public bidding window will officially close on Monday, August 17, 2026.
Here is an extended, plain-English human breakdown covering Day 2 subscription metrics, unlisted grey market trends, business operations across healthcare logistics and phlebotomy services, financial performance, valuation parameters, and key investment risk factors.
1. Day 2 Subscription Data Breakdown
By 5:00 PM on Day 2, central processing registries compiled total valid electronic application orders worth ₹758.79 crore (calculated at the upper price band cap of ₹189 per share), covering 1,212% of the net public offer.
The table below summarizes the second day's demand metrics across all investor categories:
+-----------------------------------------------------------------------------------+ | CREDENT CONNECT N CARE LIMITED: DAY 2 SUBSCRIPTION DATA | +-------------------+-----------------+------------------+------------------+-------+ | Category | Shares Offered | Shares Bid For | Subscription (x) | Value | +-------------------+-----------------+------------------+------------------+-------+ | QIB (Institutions)| 9,48,000 | 61,11,600 | 6.45x | ₹115.51Cr | NII / HNI (Wealth)| 7,08,000 | 68,87,400 | 9.73x | ₹130.17Cr | Retail (RII) | 16,56,000 | 2,71,48,800 | 16.39x | ₹513.11Cr | Market Maker | 2,52,000 | — | — | — | +-------------------+-----------------+------------------+------------------+-------+ | Total Net Offer | 33,12,000 | 4,01,47,800 | 12.12x | ₹758.79Cr +-------------------+-----------------+------------------+------------------+-------+
Analyzing the Category Inflows:
- Retail Individual Investors (RII - 16.39x): Everyday retail accounts spearheaded the volume jump on Day 2. Bids jumped from 3.11x on Day 1 to 16.39 times on Day 2, with total applications submitted for 2.71 crore shares (22,624 application lots) worth ₹513.11 crore. Under the issue rules for this SME offer, retail applicants face a minimum lot requirement of 2 lots (1,200 shares), requiring an upfront layout of ₹2,26,800 at ₹189 per share.
- Non-Institutional Investors (NII / HNI - 9.73x): High-net-worth wealth accounts and family offices stepped up their order entries, moving from 1.59x on Day 1 to 9.73 times on Day 2. HNI applicants submitted electronic orders for 68.87 lakh shares worth ₹130.17 crore. Both small-HNI (minimum 3 lots / 1,800 shares = ₹3,40,200) and big-HNI brackets saw active multi-lot bidding.
- Qualified Institutional Buyers (QIB - 6.45x): Institutional money desks expanded their participation from 1.00x on Day 1 to 6.45 times on Day 2, submitting matching cards for 61.12 lakh shares worth ₹115.51 crore.
- Market Maker Reserved Block: A dedicated block of 2,52,000 shares (~₹4.76 crore) is allocated to the designated market maker (Hem Finlease Private Limited) to provide secondary market liquidity depth post-listing.
Marquee Institutional Anchor Allocation:
Prior to opening the public issue, Credent Connect N Care raised ₹26.53 crore through its anchor investor placement on Wednesday, August 12, 2026. A total of 14,04,000 equity shares were allocated to marquee anchor investors at ₹189 per share. Anchor participants included Sunil Singhania's Abakkus Venture Opportunities Fund, Motilal Oswal Finvest, Hem Growth Opportunities Fund, Mint Focussed Growth Fund, 360 ONE LVF Treasury Solutions Fund, and LRSD Securities, establishing strong institutional backing ahead of the public launch.
2. Unlisted Grey Market Premium (GMP) & Market Sentiment
In the unofficial grey market, sentiment surrounding Credent Connect N Care has surged following strong multi-category bidding:
- Fixed Upper Price Cap Anchor: ₹189.00 per share
- Current Grey Market Premium (GMP): Tracking around +₹75.00 per share (~39.7% over issue price)
- Estimated Listing Price Range: Expected debut counter level of ₹264.00 per share
- Projected Listing Gain Margin: Indicating an immediate estimated listing upside of ~39.68%
- Retail Minimum Application Lot Size: 2 Lots / 1,200 Shares (Minimum Investment: ₹2,26,800)
What Is Driving Grey Market Optimism?
The rising grey market premium is primarily supported by two operational factors:
- Critical Specialized Healthcare Infrastructure: Cold-chain biological sample transit is a high-barrier business. Diagnostic chains cannot risk temperature spikes that ruin blood samples, giving established B2B players like Credent long-term contract stickiness.
- Massive Revenue & Profit Scaling in FY26: Revenue from operations surged 174.8% YoY to ₹214.16 crore in FY26, while net profit jumped to ₹18.45 crore, providing a solid fundamental backstop for secondary trading.
(Note: Grey market premiums represent informal, off-exchange quotes traded among dealers. They fluctuate based on daily market sentiment and broad equity benchmark trends, and should not be taken as a guaranteed listing return.)
3. Business Overview: What Does Credent Connect N Care Do?
Incorporated in June 2015 as Credent Cold Chain Logistics Private Limited and headquartered in New Delhi, Credent Connect N Care Limited is an integrated B2B healthcare services, temperature-controlled logistics, and phlebotomy workforce solutions provider.
Operating under its commercial brand C3 Logistics, the company serves as a vital back-end operational platform for diagnostic laboratories, In-Vitro Diagnostic (IVD) equipment manufacturers, pharmaceutical companies, hospitals, clinics, and corporate healthcare enterprises across India.
+-----------------------------------------------------------------------------------+ | CREDENT CONNECT N CARE BUSINESS AT A GLANCE | +-----------------------------------+-----------------------------------------------+ | Commercial Operating Brand | C3 Logistics | +-----------------------------------+-----------------------------------------------+ | Core Service Pillars | Cold-Chain Diagnostic Sample Transit, Doorstep| | | Phlebotomy, Reagent Movement, Paramedic Staffing| +-----------------------------------+-----------------------------------------------+ | B2B Client Ecosystem Depth | Associated with 2,500+ Diagnostic Labs, | | | IVD Companies, Hospitals & Pharma Majors | +-----------------------------------+-----------------------------------------------+ | Operational Field Workforce | 6,500+ Trained Field Professionals & | | | Temperature-Controlled Phlebotomy Riders | +-----------------------------------+-----------------------------------------------+ | Pan-India Network Reach | Operating across 452+ Cities & Towns in India | +-----------------------------------+-----------------------------------------------+ | Technology Integration | IoT-Enabled Temperature Trackers, Real-Time | | | TAT Monitoring & GPS Fleet Telematics | +-----------------------------------+-----------------------------------------------+
Core Competitive Moats:
1. High-Barrier Temperature-Controlled Cold Chain
Transporting blood, tissue, and biological specimens requires strict temperature maintenance (e.g., 2°C to 8°C or frozen below -20°C). Credent deploys IoT-enabled active cold boxes with real-time temperature telemetry logged on central cloud dashboards. If temperature fluctuates during transit, automated alerts trigger re-icing protocols, ensuring zero sample degradation before reaching central testing hubs.
2. Pan-India Phlebotomy & Last-Mile Field Force
With over 6,500 trained phlebotomists and field executives spanning 452+ cities, Credent handles doorstep home sample collection, stationed hospital phlebotomy, and corporate wellness health checkups. Diagnostic chains outsource home collection to Credent to avoid managing thousands of distributed on-field employees directly.
3. Deep Integration with Major Diagnostic Chains
Serving more than 2,500 laboratories and healthcare institutions creates high switching costs. Once a diagnostic network connects its central LIS (Laboratory Information System) software to Credent's logistics API for daily sample pickup routes, changing vendors risks logistical disruption and Turnaround Time (TAT) delays.
4. Detailed Financial Performance (FY24 to FY26)
An audit of Credent Connect N Care's restated consolidated financial statements reveals rapid top-line expansion alongside expanding operational and net profit margins over the last three fiscal years.
+-----------------------------------------------------------------------------------+ | CREDENT CONNECT N CARE: 3-YEAR FINANCIAL PERFORMANCE | +-------------------------------+-------------------+-------------------+-----------+ | Financial Metric (₹ in Cr) | FY24 | FY25 | FY26 | +-------------------------------+-------------------+-------------------+-----------+ | Revenue from Operations | 42.15 | 77.94 | 214.16 | | Total Income | 42.28 | 78.10 | 214.43 | | Operating EBITDA | 2.85 | 4.99 | 28.46 | | EBITDA Margin (%) | 6.76% | 6.40% | 13.29% | | Net Profit After Tax (PAT) | 1.82 | 3.61 | 18.45 | | PAT Margin (%) | 4.30% | 4.62% | 8.60% | | Total Debt / Borrowings | 8.12 | 12.45 | ~24.50 | | Net Worth | 11.20 | 16.85 | 48.20 | | Return on Net Worth (RoNW %) | 16.25% | 21.42% | 38.28% | +-------------------------------+-------------------+-------------------+-----------+
Key Financial Observations:
- Explosive Top-Line Scaling: Operating revenue expanded from ₹42.15 crore in FY24 to ₹77.94 crore in FY25, before surging 174.8% YoY to ₹214.16 crore in FY26. Growth was driven by subsidiary consolidation, expanding B2B operations, supply chain management, and higher phlebotomy sample collection volumes.
- EBITDA & Net Profit Surge: Operating EBITDA jumped from ₹4.99 crore in FY25 to ₹28.46 crore in FY26 (EBITDA margin expanding from 6.40% to 13.29%), while net profit after tax (PAT) jumped from ₹3.61 crore to ₹18.45 crore (PAT margin expanding to 8.60%). Higher revenue density across existing cold-chain transit routes boosted operating leverage.
- High Return on Net Worth: Capital efficiency improved significantly, pushing the company's Return on Net Worth (RoNW) to 38.28% in FY26.
5. Structure of the Offer & Objects of the Issue
The ₹93.90 crore public offer is structured entirely as a fresh capital issue:
+-----------------------------------------------------------------------------------+ | IPO CAPITAL STRUCTURE BREAKDOWN | +-----------------------------------+-----------------------------------------------+ | Total Issue Size | ₹93.90 Crore (49,68,000 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Fresh Issue Component | ₹93.90 Crore (100% Fresh Capital Issue) | +-----------------------------------+-----------------------------------------------+ | Offer for Sale (OFS) Component | ₹0.00 (No Selling Shareholders) | +-----------------------------------+-----------------------------------------------+ | Price Band | ₹179 to ₹189 per share | +-----------------------------------+-----------------------------------------------+ | Face Value | ₹10 per share | +-----------------------------------+-----------------------------------------------+ | Market Maker Reserved Block | 2,52,000 Shares (₹4.76 Crore Value) | +-----------------------------------+-----------------------------------------------+ | Lead Manager (BRLM) | Hem Securities Limited | +-----------------------------------+-----------------------------------------------+ | Registrar to the Issue | KFin Technologies Limited | +-----------------------------------+-----------------------------------------------+
(Source: Official Issue Prospectus)
How Will the Fresh Primary Capital Be Spent?
Because there is no Offer for Sale (OFS), 100% of the net proceeds will move directly onto the company balance sheet. Credent Connect N Care has earmarked the net proceeds for four primary areas:
- Working Capital Financing (₹37.00 Crore / 39.4%): Healthcare logistics and staffing solutions involve extended payment credit cycles from diagnostic chains and hospital networks. Infusing working capital will support cash flow requirements as revenues scale.
- Investment in Operating Subsidiaries (₹29.80 Crore / 31.7%): Injected as equity into Credent Healthcare Private Limited to fund its working capital (₹26.80 crore) and machinery CAPEX (₹3.00 crore).
- Debt Repayment / Prepayment (₹6.00 Crore / 6.4%): Paying down existing bank term loans and borrowings, reducing annual interest overheads.
- General Corporate Purposes & Issue Expenses (₹21.10 Crore / 22.5%): Supporting administrative run-rates, tech infrastructure upgrades, and issue management fees.
6. Valuation Analysis & Peer Group Comparison
At the upper price band cap of ₹189 per share, Credent Connect N Care is priced at a trailing Price-to-Earnings (P/E) multiple of 18.67x based on its restated FY26 PAT of ₹18.45 crore, establishing a post-issue corporate market capitalization of approximately ₹344.41 crore.
Let's compare this with listed logistics, healthcare support, and diagnostic service providers in India:
+-----------------------------------------------------------------------------------+ | PEER GROUP VALUATION COMPARISON | +-----------------------------------+--------------------+--------------------------+ | Company Name | Trailing P/E (x) | Primary Focus / Model | +-----------------------------------+--------------------+--------------------------+ | Credent Connect N Care (At ₹189) | ~18.67x | Healthcare Logistics & B2B| | Delhivery Limited | ~2.45x (P/S) | Third-Party Logistics | | TCI Express Ltd | ~28.50x | Express Cold Logistics | | Krsnaa Diagnostics Ltd | ~36.50x | PPP Diagnostic Support | | Metropolis Healthcare Ltd | ~54.30x | Diagnostic Testing Chain | +-----------------------------------+--------------------+--------------------------+
Valuation Summary:
At 18.67x FY26 trailing earnings, Credent Connect N Care is entering the public market at a disciplined valuation structure. While pure diagnostic chains trade at 36x to 54x P/E and express logistics players trade near 28x P/E, Credent's ~18.7x trailing P/E multiple—combined with ₹214 crore in revenue, 38.3% RoNW, and a 100% fresh issue structure—leaves a healthy fundamental margin of safety for incoming public investors.
7. Core Strengths vs. Key Business Risks
Investors evaluating this SME healthcare logistics issue should consider the following operational factors:
Key Strengths:
- Strong 12.12x Day 2 Demand Acceleration: Generating over ₹758 crore in public demand shows building market conviction.
- 100% Fresh Issue Structure: No promoter cash-out; all ₹93.90 crore raised goes into subsidiary investment, working capital, and debt reduction.
- Blue-Chip Institutional Anchor Book: Sunil Singhania's Abakkus, Motilal Oswal Finvest, and 360 ONE anchor participation signals strong institutional conviction.
- High Barrier B2B Niche: Operating nationwide cold-chain logistics across 452+ cities creates high entry barriers against generic courier firms.
Key Risk Factors:
- Customer Concentration Risk: The top five customers accounted for 59.05% of total revenue in FY26 (and top 10 contributed over 80%). Losing any key diagnostic chain partner could affect sales volumes.
- Working Capital Intensity & Trade Receivables: Trade receivables stood at approximately ₹58.83 crore in FY26, making cash flows sensitive to customer payment delays.
- Operational Transit Risks: Moving biological samples requires strict handling; temperature spikes or delays can lead to contamination claims.
8. Timeline & Allotment Steps
With the bidding window closing on Monday, here is the upcoming schedule for allotment finalization and listing:
- Public Bidding Window Closes: Monday, August 17, 2026 (5:00 PM IST)
- Basis of Allotment Finalization: Tuesday, August 18, 2026
- Refund Initiations & Unblocking of Bank Funds: Wednesday, August 19, 2026
- Credit of Equity Shares to Demat Accounts: Wednesday, August 19, 2026
- Official Stock Exchange Listing (NSE Emerge / SME): Thursday, August 20, 2026
- Designated Lead Manager: Hem Securities Limited
- Designated Registrar: KFin Technologies Limited
Application Size Matrix:
- Retail Minimum & Maximum: 2 Lots (1,200 Shares) — ₹2,26,800
- Small HNI (sNII) Minimum: 3 Lots (1,800 Shares) — ₹3,40,200
- Big HNI (bNII) Minimum: 9 Lots (5,400 Shares) — ₹10,20,600
Conclusion: What Should You Watch for on Day 3?
Credent Connect N Care presents a compelling healthcare logistics story backed by its C3 Logistics brand, pan-India presence across 452+ cities, 6,500+ field force, 38.3% RoNW returns, marquee anchor backing (Abakkus, Motilal Oswal), and a disciplined 18.67x trailing P/E entry multiple.
With Day 2 subscription surging to 12.12x overall—driven by 16.39x retail participation and 9.73x HNI demand—the issue has built strong momentum.
Over the final session on Monday, watch how institutional QIBs and big-HNIs finalize their large block orders ahead of Monday's 5:00 PM closing deadline.
Post Excerpt
A complete Day 2 analysis of the ₹93.90 crore Credent Connect N Care SME IPO. Total subscription reached 12.12x overall as retail subscribed 16.39x and HNIs touched 9.73x. Read our full review of company financials, C3 Logistics cold-chain moat, blue-chip anchor backers (Abakkus, Motilal Oswal), grey market trends (+₹75), working capital deployment, and valuation ahead of Monday's close.